Avid Bioservices Inc (CDMO)

[sun9889]

Thank you for explanation. PPHM has the same trial going on:

Front-line NSCLC: This randomized, open-label Phase II trial is evaluating bavituximab with paclitaxel and carboplatin versus paclitaxel and carboplatin in 86 front-line NSCLC patients. Patient enrollment in this trial has been completed with top-line data reported in March, 2012. Overall survival data from the trial, which is an event driven endpoint, is expected in the first half of 2013.

Do you have any idea if PPHM has any chances to beat Avastin's MOS 12.3 months and pencentage treatment change of 19.4% over control arm?